Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of EUR 16.39 billion. The enterprise value is 20.01 billion.

Market Cap	16.39B
Enterprise Value	20.01B

Important Dates

The last earnings date was Thursday, May 1, 2025.

Earnings Date	May 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.53M
Shares Outstanding	n/a
Shares Change (YoY)	+0.21%
Shares Change (QoQ)	+0.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	146.16M

Valuation Ratios

The trailing PE ratio is 11.98 and the forward PE ratio is 8.11.

PE Ratio	11.98
Forward PE	8.11
PS Ratio	1.80
PB Ratio	1.04
P/TBV Ratio	19.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.95, with an EV/FCF ratio of 8.88.

EV / Earnings	14.62
EV / Sales	2.27
EV / EBITDA	6.95
EV / EBIT	9.38
EV / FCF	8.88

Financial Position

The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.39.

Current Ratio	1.44
Quick Ratio	0.87
Debt / Equity	0.39
Debt / EBITDA	2.07
Debt / FCF	2.72
Interest Coverage	9.84

Financial Efficiency

Return on equity (ROE) is 9.19% and return on invested capital (ROIC) is 6.48%.

Return on Equity (ROE)	9.19%
Return on Assets (ROA)	5.43%
Return on Invested Capital (ROIC)	6.48%
Return on Capital Employed (ROCE)	10.43%
Revenue Per Employee	1.19M
Profits Per Employee	179,967
Employee Count	7,605
Asset Turnover	0.36
Inventory Turnover	1.00

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -46.80% in the last 52 weeks. The beta is 0.12, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	0.12
52-Week Price Change	-46.80%
50-Day Moving Average	118.16
200-Day Moving Average	150.23
Relative Strength Index (RSI)	49.90
Average Volume (20 Days)	319

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.81

Income Statement

In the last 12 months, Biogen had revenue of EUR 9.08 billion and earned 1.37 billion in profits. Earnings per share was 9.36.

Revenue	9.08B
Gross Profit	6.87B
Operating Income	2.19B
Pretax Income	1.62B
Net Income	1.37B
EBITDA	2.85B
EBIT	2.19B
Earnings Per Share (EPS)	9.36

Full Income Statement

Balance Sheet

The company has 2.40 billion in cash and 6.13 billion in debt, giving a net cash position of -3.72 billion.

Cash & Cash Equivalents	2.40B
Total Debt	6.13B
Net Cash	-3.72B
Net Cash Per Share	n/a
Equity (Book Value)	15.71B
Book Value Per Share	107.23
Working Capital	2.15B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.39 billion and capital expenditures -134.06 million, giving a free cash flow of 2.25 billion.

Operating Cash Flow	2.39B
Capital Expenditures	-134.06M
Free Cash Flow	2.25B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 75.65%, with operating and profit margins of 24.16% and 15.07%.

Gross Margin	75.65%
Operating Margin	24.16%
Pretax Margin	17.85%
Profit Margin	15.07%
EBITDA Margin	31.39%
EBIT Margin	24.16%
FCF Margin	24.82%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.21%
Shareholder Yield	-0.21%
Earnings Yield	8.35%
FCF Yield	13.75%

Stock Splits

The last stock split was on January 18, 2001. It was a forward split with a ratio of 3.

Last Split Date	Jan 18, 2001
Split Type	Forward
Split Ratio	3

Scores

Biogen has an Altman Z-Score of 3.17.

Altman Z-Score	3.17
Piotroski F-Score	n/a